Silvia Mccoll Wealth Management LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Silvia Mccoll Wealth Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 8.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,597 shares of the company’s stock after selling 515 shares during the quarter. Silvia Mccoll Wealth Management LLC’s holdings in Johnson & Johnson were worth $841,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Keener Financial Planning LLC bought a new position in Johnson & Johnson in the 4th quarter worth $40,000. WFA Asset Management Corp raised its holdings in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson in the 4th quarter worth $44,000. Disciplined Equity Management Inc. bought a new position in Johnson & Johnson in the 4th quarter worth $45,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Bank of America decreased their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Price Performance

NYSE JNJ opened at $146.03 on Wednesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market cap of $351.45 billion, a price-to-earnings ratio of 9.10, a PEG ratio of 2.43 and a beta of 0.52. The company’s 50 day moving average is $148.09 and its two-hundred day moving average is $153.97. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.68 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.